2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 1
1
Status
Recruiting
2
Active not recruiting
2
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
NET
4
Endocrine
4
Gastrointestinal
2
Sarcoma
1
Lymphoid
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
1282
Specimen Handling
927
Carboplatin
836
Magnetic Resonance Spectroscopy
834
Cyclophosphamide
807
Cisplatin
735
Nivolumab
680
Paclitaxel
635
Radiotherapy
617
Gemcitabine
580
Biopsy
559
Bevacizumab
485
Dexamethasone
444
fludarabine
410
Docetaxel
385
venetoclax
372
Oxaliplatin
367
Capecitabine
361
Fluorouracil
357
atezolizumab
350
durvalumab
340
Rituximab
335
Drug Therapy
333
Radiosurgery
321
Doxorubicin
319
Blood Specimen Collection
317
Standard of Care
311
Pemetrexed
307
Ipilimumab
303
Radiation
287
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
amino-acid, glucose, and electrolyte solution
×
1 year
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled
NCT06878664
2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
166 enrolled